Phenotypes associated with heterozygous alterations were described in B cell lymphoma and Rubinstein-Taybi syndrome 1 (41, 42), suggesting dosage-dependent EP300/CBP function. This evidence concerns the gene EP300 and B-cell non-Hodgkin lymphoma.